Teva bags first EpiPen approval
Executive Summary
Teva is “eager to begin supplying the market” with the first AB-rated substitutable generics of Mylan’s EpiPen (epinephrine) 0.3mg and EpiPen Jr. 0.15mg auto-injectables after landing US Food and Drug Administration (FDA) approval. “The company is applying its full resources to this important launch in the coming months,” the Israeli firm said. No details around pricing were disclosed by Teva. Mylan faced intense criticism for raising the price of EpiPen from about US$100 for a two-pack in 2008 to more than US$600 by 2016. In response, the company launched a half-price authorised generic at the end of the year.